Ignite Creation Date:
2026-03-26 @ 3:14 PM
Ignite Modification Date:
2026-03-30 @ 3:11 AM
Study NCT ID:
NCT07483359
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-03-19
First Post:
2026-03-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
Sponsor:
First Hospital of China Medical University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2026-03
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-06
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-05
Completion Date Type:
ESTIMATED
First Submit Date:
2026-03-16
First Submit QC Date:
None
Study First Post Date:
2026-03-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2026-03-16
Last Update Post Date:
2026-03-19
Last Update Post Date Type:
ACTUAL